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ABSTRACT
Intracranial atherosclerotic disease (ICAD) remains a leading cause of ischemic events such as stroke.
However, the use of drug coated balloons (DCBs) containing paclitaxel (PAT) in the brain vasculature
remains limited. This is the result of several factors including particulate shed from polymer excipients,
PAT toxicity, and poor blood-brain barrier (BBB) permeability of PAT. Therefore, there is a need for
novel PAT and excipient formulations for balloon coatings to improve delivery of PAT to the arterial wall
in ICAD while reducing off target drug effects and particulate shed. GM1 has previously been shown to
cross the BBB and have high specificity for the brain. GM1 can also be incorporated into liposomes for
use as a drug delivery vehicle. Therefore, specific aim-1 in this dissertation was to prepare liposomes
incorporating GM1 for use as a drug delivery vehicle for PAT. The resulting DOPC/GM1 liposomes were
around 120 nm in size with a high degree of uniformity and stability. The loading of PAT into the
DOPC/GM1 liposomes also resulted in a high encapsulation efficiency. Specific-aim 2 was to assess the
if the presence of GM1 in DOPC liposomes improves the transport of PAT across an in vitro BBB. The
presence of 0.5 mol % of GM1 in DOPC liposomes did not improve the transport of PAT across the in
vitro BBB, with the amount of PAT bypassing the hCMEC/d3 cells being similar to the control.
Therefore, higher concentrations of GM1 in DOPC liposomes were assessed. Neither 2 mol % nor 5 mol
% GM1 in DOPC liposomes improved the transport of PAT across the BBB. Specific-aim 3 was to
incorporate DOPC/GM1 liposomes into PEO thin films for future use as a balloon coating. SEM
demonstrated that the liposomes are dispersed within the PEO. The ability of PEO to interact with the
liposomes for controlled release was also assessed by dissolving PEO only and PEO + liposome films and
comparing the time to dissolve. The addition of liposomes did not affect the time to dissolve, suggesting
that additional functional groups are needed in the liposomes to sufficiently interact with PEO for
controlled release.
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Chapter 1: Introduction
1. Cerebrovascular diseases
1.1 Facts and statistics
Cerebrovascular diseases refer to conditions affecting the blood vessels and blood circulation in
the brain. A major complication of cerebrovascular diseases is ischemic stroke1. Stroke is a
leading cause of death and disability worldwide with an incidence of 156.2 per 100,000
population and mortality of 80.7 per 100,000 population in 20172. In the United States, 795,000
people have a stroke each year. In 2010, the total healthcare costs relating to cerebrovascular
diseases were $273 billion. This number is expected to triple by the year 2030, reaching $818
billion3. In addition to ischemic stroke, other complications of cerebrovascular diseases include
hemorrhagic stroke, dementias, neurological dysfunction, and neurological degeneration 1. Risk
factors for cerebrovascular diseases include age, genetics, poor diet, smoking, sedentary lifestyle,
hypertension, diabetes mellitus, weight, excessive alcohol consumption, psychosocial factors,
and high apolipoprotein ApoB/ApoA ratio1-3.
1.2 Atherosclerosis
Atherosclerosis is an underlying cause of ischemic events relating to cerebrovascular diseases1.
Atherosclerosis is characterized by the accumulation of lipids, cellular debris, and extracellular
material in the artery wall, resulting in a fatty plaque (Figure 1)4. While atherosclerosis most
commonly occurs in medium to large size arteries, it can also occur in smaller vessels with the
presence of several risk factors such as hypertension1,5,6. Because branched points in arteries
experience disrupted laminar flow that results in oscillatory flow and low shear stress, these sites
are more likely to become atherosclerotic4,6,7. Lipids accumulate in the arterial wall because of
1

the disturbed flow, activating endothelial cells to recruit monocytes to the site. These monocytes
differentiate into macrophages prior to becoming inflammatory foam-cell macrophages upon
phagocytosing lipoproteins. Additional recruitment of inflammatory cells, migration and
proliferation of vascular smooth muscle cells (VSMCs), and subsequent collagen synthesis
results in the mature atherosclerotic plaque with a fibrous cap1,4,6,7. Ischemic events such as
stroke may occur because of the reduced blood flow from the buildup of plaque or the rupturing
of the fibrous cap, which may also result in thrombosis1,4-7.

http://www.nhlbi.nih.gov/health/dci/Diseases/Hbc/HBC_WhatIs.html

Figure 1. Normal versus atherosclerotic artery resulting in reduced blood flow.
1.3 Intracranial atherosclerotic disease and its treatment
Intracranial atherosclerotic disease (ICAD) is the buildup of fatty plaque in the cerebral arteries,
occurring most commonly in the basilar artery, the middle cerebral arteries, the internal carotid
arteries, the intracranial vertebral arteries, the posterior cerebral arteries, and the anterior cerebral
2

arteries8,9. The accumulation of plaque may result in the narrowing of the lumen, thus reducing
blood flow. Moreover, the plaque may rupture, resulting in thrombus formation or embolism 9-11.
As a result, ICAD is a major cause of stroke and accounts for up to 10% of all strokes in the
United States10,11. The incidence of ICAD increases significantly with age. In a study examining
intracranial arteries via autopsy, 43% of individuals aged 60-69 demonstrated severe ICAD. The
percentage of individuals with severe ICAD increased to 80% in those ≥ 80 years9. In addition to
age, other risk factors for ICAD include hypertension, high cholesterol, diabetes mellitus,
metabolic syndrome, smoking, sedentary lifestyle, and obesity8-11.
ICAD is diagnosed using neuroimaging techniques such transcranial Doppler, magnetic
resonance angiography, and computer tomography angiography8,9,11. Catheter angiography can
also be used to diagnose ICAD and quantify the severity of the stenosis8. In addition to lifestyle
changes, the treatment for ICAD includes pharmacological intervention such as antiplatelet
drugs, statins, and antihypertension drugs8-12. Endovascular therapies such as stenting and
angioplasty have also been used to treat severe ICAD; however, these therapies have significant
limitations in the brain vasculature. In the SAMMPRIS study (Stenting vs Aggressive Medical
Therapy for Intracranial Artery Stenosis), stroke or death occurred in 14.7% of ICAD patients
treated with a stent within 30 days following stent placement compared to 5.8% in ICAD patients
treated with aggressive medical therapy consisting of pharmacological interventions and lifestyle
changes8-12. Because the stent remains in the artery long-term, stenting also carries a risk of
thrombus formation13. Angioplasty treatment without the use of a stent has demonstrated a lower
complication rate compared to treatment with a stent9. However, restenosis occurs in 5-30% of
patients treated with angioplasty alone8,12. Moreover, additional complications may occur with
angioplasty such as dissection and elastic recoil9,10.
3

Drug coated balloons (DCBs) are a technology used to peripheral and coronary artery
disease and may be a promising alternative to stents and plain balloon angioplasty for the
treatment of ICAD. Because DCBs do not remain in the vasculature long-term, they may help
reduce the increased risk of stroke and thrombosis associated with the use of stents. Moreover,
DCBs contain an antiproliferative drug such as paclitaxel (PAT) to reduce the rate of restenosis
that occurs with plain balloon angioplasty10,12. Although there is not a DCB approved by the U.S.
Food and Drug Administration (FDA) for the treatment of ICAD, several clinical trials have
examined the safety and efficacy of DCBs to treat ICAD across Europe and Asia with varying
results10,12-17.
2. Drug coated balloons
2.1 Drug coated balloon overview
DCBs containing an antiproliferative drug and polymer excipient are used to treat a variety of
atherosclerotic diseases such as peripheral artery disease and coronary artery disease. The
purpose of the antiproliferative drug is to prevent restenosis or renarrowing of the artery
following balloon inflation. Restenosis occurs because inflation of the balloon damages the
arterial wall, triggering an inflammatory cascade leading to profuse proliferation of VSMCs.
This in turn results in neointimal hyperplasia and often requires retreatment of the artery to
restore blood flow. The antiproliferative drug prevents proliferation of the VSMCs, thus
preventing restenosis18,19. PAT is the most commonly used antiproliferative agent in DCBs due
to its highly lipophilic nature, its ability to rapidly enter the intima of the artery, and its high
retention rate18-20. The use of other lipophilic drugs such as sirolimus are used less frequently in
DCBs due to the lack of ability to prevent restenosis at the same rate as PAT 18,20.
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The purpose of the hydrophilic excipient in DCBs is to improve the solubility of PAT for
rapid transfer from the balloon to the arterial wall. Moreover, the excipient can also reduce drug
loss in route to the treatment site and affect the crystallinity of PAT 19. The crystallinity of PAT
has implications for tissue retention time and the formation of embolism causing particulates.
While crystalline PAT has improved tissue retention time and sustained release, amorphous PAT
reduces particulate shed while also improving tissue solubility21. The most commonly used
DCBs to treat ICAD in clinical trials are the SeQuent Please and SeQuent Please NEO (B.
Braun, Germany), both of which use iopromide as the excipient 13,14,16,17,22.
2.2 Drug coated balloons and intracranial atherosclerotic disease
2.2.1 Clinical trials
While there are no FDA approved DCBs to treat ICAD, several clinical trials across Europe and
Asia have been carried out to explore their potential to treat ICAD. Several clinical trials have
assessed the use of the SeQuent Please (B. Braun, Germany) DCB to treat ICAD. In one study
enrolling 30 patients with severe ICAD, 3.2% of the 31 arteries treated with the SeQuent Please
DCB demonstrated restenosis. However, 2 of the 30 patients experienced ischemic stroke after
the procedure16. In another clinical trial assessing the SeQuent Please DCB for ICAD, 11.4% of
patients experienced periprocedural complications following treatment. Of the 39 lesions treated,
3 lesions (8.3%) had stenosis >50 % in the follow up period after treatment 13. The SeQuent
Please DCB was also compared to conventional stenting in another clinical trial for ICAD. In
this study, the incidence of restenosis was lower in the DCB treatment group (5.3%) compared to
the stent treatment group (34.2%); however, there was no statistical difference between groups in
terms of periprocedural complications or recurrent ischemic events17. In a clinical trial assessing
the SeQuent Please NEO (B. Braun, Germany) DCB for feasibility and safety in treating ICAD,
5

there were no periprocedural complications or deaths at the 3 month follow-up and the median
post procedural stenosis was 50%; however, the sample size was small (10 patients) and lacked
long-term data on safety and efficacy14. Another study compared the use of the Neuro Elutax SV
drug eluting balloon (Aachen Resonance, Germany) to the Wingspan stent system (Boston
Scientific, USA) for the treatment of symptomatic ICAD. Compared to the Wingspan stent
system, patients treated with the Neruo Elutax SV drug eluting balloon had significantly lower
rates of ischemic events and restenosis (64% vs 13%)15.
2.1.2 Limitations
While initial results from clinical trials assessing DCBs to treat ICAD are promising, there is
room for improvement in terms of the rates of restenosis and adverse events. One limitation in
using the Sequent Please or Sequent Please NEO DCB in cerebral arteries is that these balloons
were originally designed to treat coronary artery disease13,14,16,17. Compared to coronary arteries,
cerebral arteries are thinner and lack an elastic layer and thus require softer, more flexible
balloons to avoid complications such as arterial rupture and dissection10,14. Moreover, polymer
excipient and PAT coatings may contribute to particulate shed, leading to a life-threatening
embolism in the brain12. PAT is also cytotoxic and may have off target effects when used in the
brain. Because the use of DCBs in cerebral arteries is still in its infancy, the long-term
consequences are unknown10. In addition, the blood brain barrier (BBB) must also be considered
as PAT has poor BBB permeability23. This may prevent enough PAT from reaching the VSMCs
to be therapeutic. Therefore, a DCB designed specifically for the cerebral vascular with a novel
excipient and drug coating is needed to improve PAT BBB permeability while reducing off
target effects and particulate shed.
2.2 Tailored Medical Devices drug coated balloon technology
6

Recently, Tailored Medical Devices (TMD) developed a DCB using a novel formulation
containing polyethylene oxide (PEO) as the polymer excipient and PAT as the antiproliferative
drug for the treatment of peripheral artery disease. An advantage of the TMD formulation is that
the of weight/volume % of PEO and weight % of PAT in the formulation can be adjusted to
release PAT at specific timepoints. This helps to reduce the amount of PAT loss in the blood
stream in transit to the lesion24. When used as a coating for a single release DCB (SR-TMDDCB), the formulation produced a smooth, homogenous coating with no major defects. When
compared to the FDA approved In.PACT DCB (Medtronic, USA), the SR-TMD-DCB
demonstrated similar PAT uptake and retention in a porcine model at post treatment day 7. At
day 30, the SR-TMD-DCB demonstrated less drug retention compared to In.PACT; however the
drug amount was still considered therapeutic to prevent VSMC proliferation. The difference in
drug retention between the two DCBs is likely due to PAT existing in the crystalline state in the
In.PACT balloon and in the amorphous form in the SR-TMD-DCB. Importantly, the SR-TMDDCB also produced fewer particulates compared to the In.PACT DCB25.
In addition to the SR-TMD-DCB, TMD also developed a multiple release DCB (MRTMD-DCB) for treatment of peripheral artery disease with long, diffuse, and multiple lesions
using a single balloon with multiple inflations. This was achieved using a two-layer coating
method with the first layer consisting of the PEO and PAT formulation and the second outside
coating consisting of PEO only to reduce drug loss in transit to the treatment site. An in vitro
flow model demonstrated similar drug uptake in the first and second explanted arteries when
inflated with a single MR-TMD-DCB. The in vivo porcine model demonstrated similar results,
with a similar amount of PAT delivered to the first and second treatment sites using a single MRTMD-DCB. Moreover, at days 1 and 7 post treatment, a therapeutically relevant amount of drug
7

was retained26. Importantly, an automated coating method was recently developed for the MRTMD-DCB, demonstrating feasibility to produce the MR-TMD-DCB in an industrial setting27.
Because of its reduced particulate shed and ability to deliver PAT at specific timepoints,
the technology used in the TMD DCB formulation may have applicability in the brain for
treatment of ICAD. The MR-TMD-DCB technology offers additional advantages, in that it can
treat complex and multiple lesions with a single balloon which may help to reduce costs and
safety concerns associated with using multiple DCBs.
3. Drug delivery and the blood brain barrier
3.1 The blood brain barrier
The functions of the BBB include protecting the brain from harmful substances and regulating
the brain microenvironment. The BBB is primarily made up of endothelial cells, which line the
lumen of the blood vessels in the brain. These endothelial cells form tight junctions, creating a
physical barrier to prevent entry of certain substances from entering the brain28,29. In addition to
endothelial cells, other cell types such as pericytes, VSMCs, and astrocytes help to regulate and
maintain the BBB, forming the neurovascular unit (NVU)29-31. The layer of VSMCs decreases as
the artery size decreases, with capillaries containing a layer of pericytes instead of VSMCs 30,31.
The structure of the NVU is depicted in Figure 2.
The BBB functions in regulating ions, neurotransmitters, macromolecules, neurotoxins,
and nutrition in the brain by selectively allowing the passage of some molecules while keeping
other molecules out. Oxygen, carbon dioxide, and a wide range of lipid soluble molecules can
bypass the BBB passively through diffusion. Although tight junctions prevent macromolecules
and polar molecules from entering the brain, essential polar molecules such as glucose and
amino acids can enter the BBB via transporters. Macromolecules and peptides can also bypass
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the BBB through endocytosis mechanisms. ATP-binding cassette (ABC) transporters function to
remove lipid soluble molecules such as neurotoxins from the brain. These ABC transporters also
prevent the entry of many lipid-soluble drugs because although many lipid-soluble molecules can
enter the BBB through diffusion, lipid-soluble drugs are often a substrate for the ABC efflux
transporters28,29.

Kisler K, Nelson AR, Montagne A, Zlokovic BV. Cerebral blood flow regulation and
neurovascular dysfunction in Alzheimer disease. Nat Rev Neurosci 2017;18(7):419-434.

Figure 2. Structure of the Neurovascular Unit.
3.2. Nanoparticles as a drug delivery vehicle
Nanoparticles range from 1-1000 nm in size and are widely studied as a drug delivery vehicle to
transport drugs across the BBB to treat a variety of diseases32-34. In general, nanoparticles do not
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disrupt the integrity of the BBB tight junctions, offering an advantage over other drug delivery
methods such as opening the BBB with ultrasound, osmotic pressure, or microbubbles33.
Because of their small size, nanoparticles can also enter the smallest capillaries 6-9 µm in
diameter along with cells 10-20 µm in diameter, allowing them widespread reach in the body32.
In addition, nanoparticles can be modified with a variety of surface coatings to improve their cell
or tissue specificity and reduce off-target effects34. The different types of nanoparticles are vast
and include inorganic nanoparticles, solid lipid nanoparticles, polymeric nanoparticles, nanogels,
micelles, liposomes, dendrimers, nanoemulsions, exosomes, quantum dots, and
polymersomes32,33.
3.2.1 Liposomes
Liposomes are a type of nanoparticle composed of phospholipids, forming a sphere with a lipid
bilayer in an aqueous environment. Liposomes are primarily formed by weak interactions
including Vander waal forces, hydrophilic interactions, and hydrogen bonding with water.
Liposomes are commonly used as a drug delivery vehicle and can accommodate both
hydrophilic and hydrophobic drugs due to their lipid bilayer (Figure 3)32-36. In addition,
liposomes have excellent biocompatibility and are biodegradable32,33,35. Moreover, various
ligands, polymers, proteins, and other molecules can be added to the liposome to improve drug
delivery and target specificity32-34,37. Furthermore, there is evidence that PAT exists in the
amorphous form instead of the crystalline form within a liposome membrane; this is
advantageous as amorphous PAT is associated with fewer embolism causing particulates in the
blood stream21,38. Because of these characteristics, liposomes are often studied as a drug delivery
vehicle for crossing the BBB and for the treatment of atherosclerotic diseases32-35,37,39-41.
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Figure 3. Cross Section of a Liposome.
3.2.1.1 Liposome modifications

Liposomes may be modified to improve stability, organ specificity, and drug delivery.
Cholesterol is commonly added to liposomes because cholesterol increases increase the packing
of density of phospholipids within the bilayer. This helps to reduces potential interactions
between the fatty acid chains and proteins, thus increasing the liposome stability 36. In addition to
cholesterol, polyethylene glycol or polysaccharides may also be added to liposomes to improve
stability by forming a protective layer to prevent binding of plasma proteins, thus improving
circulation time36,42. PEGylation of liposomes may also improve BBB permeability. Ligands
such as antibodies, aptamers, and peptides can also be added to liposomes to improve transport
across the BBB. These ligands can bind to receptors located on the endothelial cells comprising
the BBB, facilitating receptor-mediated transcytosis. The addition of cationic lipids to liposomes
may also improve BBB transport as a result of the positively charged lipids interacting with the
negatively charged membrane of the endothelial cells in the BBB, facilitating adsorptivemediated endocytosis42.
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3.2.1.2 Liposome preparation
The thin film hydration method with extrusion is a well-established, commonly used method to
prepare liposomes. After evaporating organic solvent from the lipids, a thin film is formed. The
thin film is then hydrated in aqueous buffer to form liposomes. At this stage in liposome
preparation, the liposome structures present vary and consist mainly of multilamellar vesicles
>500 nm in diameter. Multivesicular vesicles >1000 nm in diameter may also be present.
Extrusion through a polycarbonate membrane with a set pore size is used to improve the
uniformity of the liposomes. This results in unilamellar vesicles with a diameter that depends on
the pore size of the polycarbonate membrane that was used. In addition to thin film hydration,
other methods to prepare liposomes include reverse phase evaporation, solvent injection
techniques, detergent removal, and microfluidization. In addition to extrusion, size reduction of
liposomes can also be achieved though sonication or homogenization36,43.
3.2.2 GM1
Monosialoganglioside (GM1) is a type of ganglioside commonly found in the plasma membrane
of mammalian neurons. The chemical structure of GM1 is depicted in Figure 4. GM1 has
neuroprotective properties and functions in neuroplasticity, neuritogenesis, neuro repair, cell
differentiation, cell signaling, and calcium regulation44,45. A study by Zou et al 2017 recently
demonstrated GM1 micelles loaded with doxorubicin can cross the BBB in vivo45. In addition,
several studies have used GM1 micelles to encapsulate PAT for drug delivery 46,47. Because of its
amphiphilic nature, GM1 can be also incorporated into liposomes44,48-54.This may help reduce the
amount of GM1 needed and reduce the cost burdens associated with GM1 use. In addition, GM1
may help stabilize liposomes under physiological conditions54.
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Figure 4. Chemical structure of GM1.
4. Main goal, specific aims, and hypothesis
The goal of this dissertation is to prepare PAT loaded liposomes containing GM1, assess the
ability of these PAT loaded GM1 liposomes to cross an in vitro model of the BBB, and to assess
the ability of GM1 liposomes to crosslink with PEO for future use as a balloon coating. The goal
will be achieved using the following specific aims:
Specific Aim 1: To prepare liposomes incorporating GM1 and to load PAT into these
liposomes.
Hypothesis: PAT can be loaded into a liposome incorporating GM1.
Specific Aim 2: To assess the ability of PAT loaded GM1 liposomes to cross an in vitro
model of the BBB.
Hypothesis: The presence of GM1 will improve the ability of PAT loaded liposomes to cross an
in vitro BBB.
Specific Aim 3: To assess the ability of GM1 liposomes to crosslink with PEO.
Hypothesis: Liposomes incorporating GM1 lack sufficient functional groups to cross link with
PEO.

13

Chapter 2: Preparation and Characterization of DOPC/GM1 Liposomes
Abstract
Liposomes are commonly used as a drug delivery vehicle for drugs such as paclitaxel (PAT) and
can be modified to improve stability, blood brain barrier (BBB) permeability, and organ
specificity. Once such modification is the addition of GM1 to liposomes as GM1 have previously
demonstrated BBB permeability. In this study, a protocol was first established for preparing
liposomes. Next, DOPC liposomes containing different mol percentages (0, 0.5, 2, and 5) of
GM1 were prepared and loaded with PAT. The resulting liposomes were around 120 nm in
diameter with a high degree of uniformity and a high encapsulation efficiency of PAT. The
liposomes were also stable in terms of diameter and polydispersity index through at least 14
days. In addition, atomic force microscopy confirmed the presence and spherical morphology of
the DOPC/GM1 liposomes.
1. Introduction
Therapies that improve the permeability of drugs across the blood brain barrier (BBB) while
maintaining its integrity are needed for neurological diseases including intracranial
atherosclerotic disease (ICAD). Several clinical trials have assessed the use of drug coated
balloons (DCBs) to treat the atherosclerotic lesions present in ICAD, helping to restore blood
flow and reduce the rate of restenosis or re-narrowing of the artery. However, these trials have
mixed results and several limitations, including the use of paclitaxel (PAT), which has poor BBB
permeability and potential off-target, toxic effects in the brain13-17,23. Therefore, a drug delivery
method that improves PAT BBB permeability and specificity is needed to improve the outcomes
for patients with ICAD.
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Liposomes are a widely used drug delivery vehicle for a variety of diseases. In an
aqueous environment, phospholipids will spontaneously form spherical vesicles with a lipid
bilayer that can accommodate both hydrophilic and hydrophobic drugs32-35. In addition,
liposomes have excellent biocompatibility and biodegradability32,33,35. Importantly, liposomes
can also be modified with functionalized lipids and various coatings to improve drug delivery for
specific tissues and diseases32-34,37.
One way to improve the transport of liposomes across the BBB may be to incorporate the
ganglioside GM1 into the liposomal membrane. A previous study demonstrated the ability of
GM1 micelles to improve the transport of doxorubicin across the in vivo BBB and target the
brain with high specificity45. Incorporating GM1 into liposomes may help reduce the amount of
GM1 needed to bypass the BBB, which in turn will help reduce the cost burden associated with
using GM1 micelles.
Several studies have also used liposomes to encapsulate PAT38,55-60. One such study by
Zhang et al synthesized liposomes consisting of 1,2-dioleoyl-sn-glycero-3-phosphocholine
(DOPC), cholesterol, and cardiolipin using the thin film hydration method with extrusion to
improve the delivery of PAT for various types of cancers55. Importantly, several studies have
also incorporated GM1 into DOPC liposomes48-50,52.
The purpose of this study is to prepare DOPC/GM1 liposomes loaded with PAT. This
will be achieved using the well-established thin film hydration followed by extrusion method for
preparing liposomes55,61,62. Liposome diameter, uniformity, morphology, and drug encapsulation
efficiency will be assessed and used to confirm the presence of liposomes.
2. Materials and Methods
2.1 Materials
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Phosphate buffer saline (PBS), methanol, high performance liquid chromatography (HPLC)
grade water, acetonitrile, ethyl acetate, and chloroform were purchased from Milipore Sigma (St.
Louis, MO). Ethanol (200 proof) and Cobalt(II) chloride hexahydrate (CoCl2) were purchased
from Fisher Scientific (Hanover Park, IL). DOPC, Heart CA cardiolipin (heart,bovine),
cholesterol, L-α-phosphatidylcholine (Egg PC) (Egg, Chicken), and ganglioside GM1 (ovine
brain) were purchased from Avanti Polar Lipids (Alabaster, AL). Paclitaxel (PAT) was
purchased from ChemiTek (Indianapolis, IN). Calcein was purchased from Cayman Chemical
(Ann Arbor, MI).
2.2 Preparation of liposomes
DOPC, Egg PC, cardiolipin, and GM1 were dissolved in chloroform. Cholesterol and PAT were
dissolved in ethanol. Liposomes were prepared using the thin film hydration method followed by
extrusion55,61. Lipids in their respective organic solvent with or without PAT were added to a
round bottom flask in the appropriate molar ratios. When included, PAT was added in a 30:1
lipid:drug molar ratio. The following liposome formulations and molar ratios were used:
DOPC/cholesterol/cardiolipin (90:5:5), Egg PC, DOPC, Egg PC/cholesterol (95:5),
DOPC/cholesterol/cardiolipin/GM1 (89:5:5:1), DOPC/GM1 (99.5:0.5), DOPC/GM1 (98:2), and
DOPC/GM1 (95:5). Prior to identifying the final method for preparing liposomes, several aspects
were adjusted in the method including organic solvent evaporation (time, vacuum), lipid
hydration (time, rpms, temperature), hydration buffer (water, PBS, MBSE), addition of
freeze/thaw cycles following hydration, sonication vs extrusion for formation of liposomes, the
method for cleaning glassware, and grease use on the rotary evaporator. The final method used
for preparing liposomes is as follows: organic solvent was evaporated using a rotary evaporator
(Buchi) under vacuum. The round bottom flask was rotated at 100 rpms in a 37°C water bath for
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1 hour. The subsequent lipid thin film was placed under a high vacuum (<1000 mTorr) overnight
to remove residual solvent. The following day, an aqueous buffer (water, PBS, or MBSE) was
added to the lipid film, so the final concentration of lipid was 3 to 6 mM. The lipid film was then
hydrated on a rotary evaporator under atmospheric pressure at 200 rpms in a 40°C water bath for
1 hour. Next, the lipid suspension underwent 5 freeze thaw cycles using a dry ice/ethanol bath
and a 40°C water bath. The lipid suspension was then extruded 19 times through a 0.8, 0.4,
and/or 0.1 µm polycarbonate membrane (Avanti Polar Lipids). Liposome size and polydispersity
index (PI) were determined using dynamic light scattering (DLS) in a Beckman Delsa Nano C
instrument.
2.3 Rhodamine B entrapment and confocal microscopy
A DOPC/cholesterol/cardiolipin (90:5:5) thin film was prepared following the method described
by Zhang et al 200555. A 1 mg/mL stock of Rhodamine B was prepared. 53 µL of the stock
solution was added to 2.947 mL of water, which was then added to the lipid film for hydration.
Following hydration, the lipid suspension was extruded through a 0.4 µm membrane. The
lipid/Rhodamine B suspension was then added to a Float-A-Lyzer G2 dialysis device and placed
in deionized water with light stirring. The water was changed every 3 hours for a total of 9 hours
to remove free Rhodamine B. The lipid/Rhodamine B suspension was then viewed under a
confocal microscope (Olympus, Japan).
2.3 Atomic Force Microscopy
Atomic force microscopy (AFM) was used to visualize the presence and morphology of
liposomes. Prior to imaging, liposomes were diluted 1:10 to 1:50 with deionized water and a
volume ≤ 50 µL was placed on a glass cover slip to air dry. To decrease the dry time, a light
stream of nitrogen was directed at the liposome suspension droplet. Immediately upon drying,
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vesicles were visualized using an AFM (Asylum Research, Santa Barbra, CA) in AC air mode
with a silicon probe (AC240TS-R3, Oxford Instruments). A resonance frequency of 70 kHz and
spring constant of 2 Nm-1 was used. 512 X 512 pixel height and amplitude images were acquired
using a scan rate of 0.6 Hz.
2.4 Calcein and cobalt quenching assay
The Calcein and cobalt quenching assay was performed as described by MacDonald et al61.
Following evaporation of organic solvent, liposomes were hydrated in MBSE buffer so the final
concentration was 6 mM. 2 µL of 0.01 M calcein (pH 7) was added to 0.2 mL of liposomes. The
liposome/calcein suspension was then diluted by adding 1 µL to 0.36 mL MBSE buffer. The
fluorescence was read in plate reader (excitation/emission 490/520 nm). 5 mM CoCl2 was then
added to quench fluorescence and sample fluorescence was read in plate reader. This process
with calcein and CoCl2 was repeated at various steps of liposome preparation including before
freeze/thaw cycles, after freeze/thaw cycles, extrusion 3 times through a 0.1 µm membrane,
extrusion 7 times through a 0.1 µm membrane, extrusion 11 times through a 0.1 µm membrane,
extrusion 15 times through a 0.1 µm membrane, extrusion 19 times through a 0.1 µm membrane,
and 1 hour following extrusion. As calcein becomes more encapsulated into vesicles,
fluorescence following the addition of CoCl2 should increase with progressing steps of liposome
preparation. This is because CoCl2 quenches calcein fluorescence; therefore, encapsulation of
calcein within a vesicle should “protect” it from CoCl2 quenching. During troubleshooting,
various aspects of this assay were adjusted including organic solvent evaporation (rpms, time,
vacuum), liposome hydration (rpms, time, PBS vs MBSE buffer), the lipid used (Egg PC vs
DOPC), pH of calcein, cleaning method of glassware, and grease use in the rotary evaporator.
2.5 Paclitaxel encapsulation efficiency within liposomes
18

The encapsulation efficiency of PAT within liposomes was determined using a method modified
from Nanda et al38. A gel chromatography column was prepared by placing a small cotton ball
on the bottom of a 3 mL plastic syringe with the plunger removed. Sephadex G-25 was prepared
by swelling in PBS. The prepared Sephadex G-25 was then used to fill the column. The column
was placed in a 15 mL conical tube to collect excess buffer and eluted sample. The column was
then centrifuged to remove excess buffer. Following extrusion, 1 mL of the liposome/PAT
suspension was added to the column and centrifuged at 50 x g for 10 minutes followed by 1000 x
g for 3 minutes to expel liposome material from column. When recovering free PAT from the
column, ethanol was added to column and centrifuged at 1000 x g for 3 minutes and the eluted
sample was collected in a fresh tube. Encapsulated PAT was released from liposomes by adding
ethanol (0.2 mL liposomes, 1.8 mL ethanol) or ethyl acetate (0.2 mL liposomes, 2 mL ethyl
acetate). If ethanol was used to disrupt the liposome membrane, the sample was first sonicated
for 15 minutes and then passed through a 0.2 µm membrane before HPLC. If ethyl acetate was
used, sample was inverted three times and centrifuged to separate the organic layer from the
aqueous layer. The organic layer was then collected and transferred to the rotary evaporator to
evaporate. Following evaporation, the sample was resuspended in 1 mL of ethanol prior to
HPLC. HPLC for PAT quantification is described in section 2.6. The encapsulation efficiency of
PAT was calculated as follows: (encapsulated PAT in µg/initial PAT added to lipids in µg) *
100%.
2.6 Drug quantification
Samples containing PAT in ethanol were quantified using a previously developed method using
HPLC25. HPLC analyses was performed on a Waters e2695 system equipped with a Waters
2489 UV/Vis detector (Waters Corporation, Milford, MA) and a Nova-Pak column (3.9 mm x
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150 mm, particle size: 4 μm). A 45:55 water:acetonitrile mobile phase was used. The column
temperature was set to 35°C, the flow rate was set to 1 mL/min, and 10 µL of sample was
injected for analysis. The UV detector wavelength was set to 227 nm. Prior to sample analysis, a
PAT calibration was prepared to calculate the concentration of PAT present in the sample.
Concentration was determined by measuring the area under the curve for each sample.
3. Results
3.1 Troubleshooting DOPC/cholesterol/cardiolipin (90:5:5) liposomes
For the first attempt at preparing liposomes, the thin film hydration followed by extrusion
method described by Zhang et al 2005 was used 55. This method used a
DOPC/cholesterol/cardiolipin (90:5:5) liposome formulation, which was also used in the current
study. Organic solvent was evaporated from the lipids overnight on a rotary evaporator. The film
was then hydrated in PBS at 200 rpm at 40 °C. The suspension was then extruded through a 0.2
µm followed by a 0.1 µm membrane. Using DLS, the nanoparticles had a diameter of ~120 nm
and a PI near 0.1, indicating a high degree of uniformity. However, it was observed these
nanoparticles remained stable in diameter and PI for many months, suggesting that these
nanoparticles may not be liposomes. Therefore, in addition to DLS, another method was needed
to confirm the presence of liposomes. To try to visualize the nanoparticles, Rhodamine B dye
was added to the hydration step and the suspension was extruded through a 0.4 µm membrane to
achieve a diameter that could be visualized using confocal microscopy. If liposomes were
present, fluorescent spheres should be present when viewed under the confocal microscope as the
Rhodamine B dye should encapsulate into liposomes. However, no spheres were present when
viewed. DLS was then performed to confirm the nanoparticles had a diameter near the 400 nm
expected when using a 0.4 µm membrane for extrusion. Instead, the nanoparticles had a diameter
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of 205.4 nm and PI of 0.209. This suggested that there may be an issue with the liposome
preparation method as it appears the nanoparticles were spontaneously becoming smaller.
Various parameters of the hydration step were modified to try to increase the diameter of the
liposomes. First, the liposomes were hydrated at 50 rpm for 15 minutes followed by 100 rpm for
5 minutes. Immediately following hydration, the suspension was analyzed using DLS. DLS
indicated a diameter of 1071.9 nm and polydispersity index of 0.377. However, after extruding
through a 0.8 µm membrane, nanoparticles had a diameter of ~300 nm. This suggests the
nanoparticles were again spontaneously becoming smaller. The hydration step was then modified
again to 100 rpm for 15 minutes. Immediately following hydration, DLS indicated a diameter of
723.8 nm and PI of 0.313. After extrusion through a 0.8 µm membrane, DLS indicated a
diameter of 242.6 nm and PI of 0.233, a diameter not consistent with the use of a 0.8 µm
membrane. Next, a different hydration method described by Hongwei Zhang was used63.
Following the addition of PBS, the thin film was vortexed 3 times for 10 seconds to disperse the
film. Next, the suspension was left at 4ºC overnight to hydrate. The next day, the suspension was
extruded through a 0.4 µm membrane. On day 0, DLS indicated a diameter of 442.1 nm and PI
of 0.192. This diameter is consistent with what would be expected with extrusion through a 0.4
µm membrane. However, on day 1, the diameter decreased to 252.4 µm with a PI of 0.174. This
suggested the nanoparticles spontaneously became smaller, which is not consistent with
liposomes. It was hypothesized that the vacuum on the rotary evaporator was not sufficient to
remove residual solvent, causing problems with producing liposomes. Therefore, following
evaporation of the organic solvent on the rotary evaporator, the film was placed under an 80 kPa
vacuum overnight. Following the hydration method from Hongwei Zhang, the suspension was
extruded through a 0.4 µm membrane. DLS indicated a diameter of 220.7 nm and PI of 0.172,
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which again suggested a lack of liposomes. Finally, using the original liposome method by
Zhang et al 2005, the nanoparticle suspension was visualized using AFM. AFM revealed a
morphology consistent with a lipid film rather than individual liposomal spheres (Figure 5). This
indicated liposomes were likely not being produced and further troubleshooting and optimization
was needed.
3.2 Troubleshooting Egg PC liposomes and the calcein and cobalt quenching assay
MacDonald et al 1991 was the first study to report using extrusion as a method for preparing
liposomes61. In the study, authors used liposomes prepared from Egg PC and confirmed the
presence of an internal compartment using a calcein and cobalt quenching assay. In the assay,
calcein is added to the hydrated film prior to extrusion. The suspension then undergoes
freeze/thaw cycles prior to extruding through the desired membrane to encapsulate the calcein
within the vesicles. Fluorescence of the sample is then measured. Next, cobalt is added to the
suspension, which quenches calcein fluorescence. If there is not an internal compartment in the
vesicles, calcein fluorescence should be quenched. In contrast, if there is an internal
compartment, calcein should be “protected” within the vesicle compartment from cobalt
quenching and fluorescence should be similar to the initial value measured prior to the addition
of cobalt. This calcein and cobalt quenching assay was utilized in the current study using Egg PC
to prepare liposomes. Calcein fluorescence before and after the addition of cobalt was measured
during the following steps of preparation: Immediately before the freeze/thaw cycles,
immediately after the freeze/thaw cycles, after extruding 3, 7, 11, 15, and 19 times through a 0.1
µm membrane, and 1 hour following extrusion. It was thought that as calcein became
increasingly encapsulated within the vesicle compartment with additional each step of liposome
preparation, fluorescence following the addition of cobalt should increase with each step until
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fluorescence is similar to the value measured prior to the addition of cobalt. This was not
observed. Instead, cobalt quenched nearly all fluorescence at each step, suggesting a lack of an
internal compartment. Various parameters were adjusted to try to troubleshoot the preparation of
liposomes and the assay including the organic solvent evaporation step, the hydration of the film,
the lipid used (Egg PC vs DOPC), the pH of reagents, and the amounts of caclein and cobalt used
with similar results. A representative calcein with cobalt quenching assay is shown in Figure 6.
3.3 Preparation of Egg PC liposomes
During preparation of Egg PC liposomes, it was observed that following the hydration step, the
lipids appeared to clump to together in large chunks rather than evenly disperse throughout the
hydration buffer. This information was relayed to support at Avanti Polar Lipids and it was
suggested a contaminant was present. To address this issue, all glassware used to prepare
liposomes was cleaned with organic solvent followed by heating in a 300 ºC oven to remove all
residual contaminants. The rotary evaporator was also taken apart and cleaned and the use of any
grease was discontinued. New lipids and solvents were also ordered. Following the evaporation
of organic solvent, the film was also placed under a vacuum <1000 mTorr to remove any
potential residual organic solvent contaminated. This led to the final liposome preparation
method described in section 2.2. Following these changes, it was observed that the lipid film
appeared opaque and covered the entire area of the round bottom flask. This differed from
previous attempts where the film appeared translucent and only gathered in a small circle on the
bottom of the round bottom flask. Following the hydration step, the lipid film became completely
dispersed and did not gather in chunks like previously observed. Prior to extruding, DLS
indicated that the vesicles had a diameter of 2501.9 nm and a PI of 0.217, which would be
expected for vesicles that had not yet been extruded through a small pore membrane. Following
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extrusion through 0.8, 0.4, and 0.1 µm membranes, DLS indicated diameters of 801.3, 442.4,
128.5 nm, respectively. These diameters are consistent what would be expected using these sizes
of membranes (Table 1). The stability of the vesicles extruded through the 0.4 µm and 0.1 µm
membranes were also monitored for 7 days. The vesicles extruded through the 0.1 µm membrane
appeared stable in terms of diameter and PI for 7 days. In contrast, vesicles extruded through the
0.4 µm membrane decreased in diameter 294.1 nm on day 7. On day 7, the 0.4 µm suspension
also appeared cloudy (Table 2). These results indicate a lack of stability. Next, Egg
PC/cholesterol (90:10) liposomes were prepared with PAT to further confirm the presence of
liposomes and to determine the encapsulation efficiency of PAT within these liposomes. Prior to
extruding, these Egg PC/cholesterol/PAT liposomes had a diameter of 1921.3 nm and PI of
0.265, consistent with vesicles that had not been extruded through a membrane. Following
extrusion through a 0.1 µm membrane, the vesicles had a diameter of 131.8 nm and PI of 0.096.
After the suspension was ran through a gel chromatography column, the eluted sample was
analyzed under DLS to confirm the liposomes had been eluted out. The collected sample had a
diameter of 131.1 nm and PI of 0.104, which are similar to values measured prior to running the
suspension through the column (Table 3). Following HPLC analysis, it was determined that PAT
had an encapsulation efficiency of 57.7 % when loaded into Egg PC/cholesterol (90:10)
liposomes. 8.4% of the initial PAT added to the lipids was recovered from the column (Table 4).
The unaccounted PAT was likely lost at various steps to the plasticware and glassware used.
Taken together, these results provide strong evidence for the presence of liposomes.
3.4 Preparation of DOPC/cholesterol/cardiolipin liposomes with and without GM1
Prior to extrusion, DOPC/cholesterol/cardiolipin (90:5:5) vesicles with PAT were 866.8 nm in
diameter and had a PI of 0.284. Following extrusion through a 0.4 µm membrane, vesicles
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measured 272.9 nm with a PI of 0.160. After extrusion through a 0.1 µm membrane, vesicles
were 125.0 nm with a PI of 0.086. After running through a gel chromatography column, the
eluted sample had a diameter of 122.0 nm and PI of 0.078, which is consistent with measurement
taken prior to chromatography (Table 5). The PAT encapsulation efficiency was calculated to be
68.4 % and the amount of free PAT remaining on the column was calculated to be 5.9 % (Table
6). Liposomes prepared with 0.4 µm and 0.1 µm remained stable in terms of diameter and PI for
at least 14 days (Table 7). While the diameter of DOPC/cardiolipin/cholesterol (90:5:5)
liposomes were smaller than expected with the use of a 0.4 µm membrane, there was a high
encapsulation of PAT. Therefore, it is possible DOPC/cholesterol/cardiolipin (90:5:5) liposomes
are more energetically favorable at around 250-300 nm than 400 nm. Therefore, we continued
with adding GM1 to DOPC/cholesterol/cardiolipin liposomes. Prior to extrusion,
DOPC/cholesterol/cardiolipin/GM1 (89:5:5:1) vesicles with PAT had a diameter of 1348.0 nm
and PI of 0.347. Following extrusion through a 0.2 µm membrane, vesicles were 185.5 nm with a
PI of 0.094 and after extrusion through a 0.1 µm membrane, vesicles were 119.3 nm with a PI of
0.053. When eluted through a gel chromatography column, the collected sample had a diameter
of 118.9 and PI of 0.091, consistent with the prior 0.1 µm membrane measurements (Table 8).
However, no PAT was detected following chromatography and solvent disruption of the vesicles.
This suggested that because there was no PAT, it is possible the
DOPC/cholesterol/cardiolipin/GM1 (89:5:5:1) formulation does not form liposomes.
3.5 Preparation of DOPC liposomes with different mol percentages of GM1
To rule out an unfavorable interaction between GM1 and cardiolipin and/or cholesterol and to
simplify the liposome formulation, DOPC alone was used to prepare liposomes with GM1. Also,
it was discovered that ethyl acetate is necessary to disrupt and release drug from vesicles
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containing GM145,46. Prior to using ethyl acetate, ethanol was used for this step. The following
liposome formulations were prepared without PAT and extruded through a 0.1 µm membrane:
DOPC and DOPC/GM1 (99.5:0.5). The following liposome formulations were prepared with
PAT and extruded through a 0.1 µm membrane: DOPC, DOPC/GM1 (99.5:0.5), DOPC/GM1
(98:2) and DOPC/GM1 (95:5). The addition of GM1 to DOPC liposomes did not have an impact
on liposome diameter or PI. Moreover, the addition of PAT did not have an impact on liposome
diameter or PI. All liposome formulations had a diameter around 120 nm and PI <0.1, indicating
a high degree of uniformity (Table 9). In liposomes loaded with PAT, DOPC and DOPC/GM1
(99.5:0.5) liposomes remained stable up to day 56 in terms of diameter. DOPC/GM1 (98:2) and
DOPC/GM1 (95:5) diameters remained stable up to day 14 (Figure 7A). In terms of PI, DOPC
liposomes remained stable until day 56 when the PI significantly increased. DOPC/GM1
(99.5:0.5) liposomes remained stable through day 56. DOPC/GM1 (98:2) liposomes remained
stable through day 14. DOPC/GM1 (95:5) remained stable until day 14 when the PI increased
(Figure 7B). The encapsulation efficiencies of PAT loaded into the different DOPC and
DOPC/GM1 formulations were similar at around 60-70%, indicating an amount of PAT
encapsulated within the vesicles (Figure 8). AFM was also performed on DOPC/GM1 (99.5:0.5)
liposomes and confirmed a spherical morphology consisted with liposomes (Figure 9)64.
4. Discussion
Because of the poor BBB permeability and cytotoxicity of PAT, a drug delivery vehicle is
needed to improve the delivery and specificity of PAT to improve treatment outcomes for
patients with ICAD. Liposomes are a promising drug delivery vehicle for PAT because of their
ability to accommodate hydrophilic and hydrophobic drugs, high degree of biocompatibility, and
biodegradability32-35. In addition, liposomes can be modified with various molecules such as
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GM1, which has previously demonstrated a high degree of BBB permeability and brain
specificity45. In this study, we successfully incorporated GM1 into liposomes and loaded PAT
within these liposomes for future studies regarding drug delivery, the BBB, and ICAD treatment.
After several trials using different lipid formulations, preparation methods, and assays for
liposome confirmation, a final method was established for preparing DOPC and DOPC/GM1
liposomes. This method resulted in the formation of liposomes that were around 120 nm in
diameter with a high degree of uniformity. DOPC and DOPC/GM1 liposomes were also able to
load PAT with a high drug encapsulation efficiency between 60-70 %. While the DOPC and
DOPC/GM1 liposomes remained stable in terms of diameter and uniformity up to 56 days
depending on the formulation, this is not inconsistent with the literature. Once study reported
stability of liposome diameter and PI up to 5 months65. Therefore, continued monitoring of the
DOPC and DOPC/GM1 formulations may reveal an increase in diameter and PI indicative of
instability. Moreover, it is important to note that when using DLS, it is assumed the nanoparticles
are spherical in morphology. If instability results in different morphologies, DLS may not be an
accurate assessment of stability. Therefore, it may also be beneficial to monitor stability through
visual means such as AFM.
In the future, additional characterization of the DOPC/GM1 liposomes is needed. The
release profile of PAT from the liposomes needs to be determined to confirm sustained release of
PAT. Moreover, the zeta-potential needs to be determined as it can provide insight into the
stability of the liposomes. It may also be beneficial to perform differential scanning calorimetry
to determine the crystallinity of PAT, which has implications for embolism formation in the
bloodstream21. Fourier-transform infrared spectroscopy can also be used to confirm the make-up
of different liposome formulations. Modifications of the liposomes may also be needed such as
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the addition of cholesterol, which can improve liposome stability and drug release66. In addition,
it may be beneficial to perform AFM on DOPC/GM1 liposomes with 2 and 5 mol % GM1 to
confirm the increasing amount of GM1 does not significantly alter liposome morphology and
integrity, which has been reported in the literature49.
5. Conclusion
In this study, DOPC, DOPC/GM1 (99.5:0.5), DOPC/GM1 (98:2), and DOPC/GM1 (95:5) were
successfully prepared and loaded with PAT. Future studies will determine if the presence of
GM1 in a liposome can improve the transport of PAT across an in vitro model of the BBB.
Additional characterizations and modifications of the liposomes will also be needed.
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Figure 5. AFM of DOPC/cholesterol/cardiolipin (90:5:5) liposome formulation. AFM revealed
the presence of film structures rather that individual liposomal spheres.
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Figure 6. Representative calcein and cobalt quenching assay. Calcein was added to the lipid
suspension following the hydration step. Initial calcein fluorescence (w/o cobalt- blue) was
measured at each step in liposome preparation. Then CoCl2 was added (w/ cobalt- orange) to an
aliquot of lipid/calcein suspension at each step of liposome preparation and fluorescence was
measured again. Calcein fluorescence after CoCl2 addition did not increase with each subsequent
step of liposome preparation for all assays tested, suggesting a lack of an internal compartment.
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Table 1. Egg PC liposome diameter and polydispersity index after various stages of liposome
preparation. Egg PC liposomes were prepared using the thin film hydration method followed by
extrusion through 0.8, 0.4, and 0.1 µm membranes. Liposome diameter and polydispersity index
was determined using dynamic light scattering.

Step

Diameter (nm)

Polydispersity index

Pre-extrusion

2501.9

0.217

0.8 µm membrane

801.3

0.295

0.4 µm membrane

442.4

0.299

0.1 µm membrane

128.5

0.056
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Table 2. Stability of Egg PC liposomes extruded through a 0.4 µm or 0.1 µm. Prior to extrusion
through membranes, liposomes were prepared using the thin film hydration method. Liposome
diameter and polydispersity index was determined using dynamic light scattering. The *
indicates the liposome suspension appeared cloudy on this day.

Day

0.4 µm
membrane
diameter (nm)

0.4 µm
membrane
polydispersity
index

0.1 µm
membrane
diameter (nm)

0.1 µm
polydispersity
index

0

442.4

0.299

128.5

0.056

2

458.3

0.324

126.4

0.090

5

426.1

0.287

126.4

0.105

7*

294.1

0.156

126.6

0.052
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Table 3. Diameter and polydispersity index of Egg PC/Cholesterol (90:10) loaded with PAT.
Liposomes were prepared using the thin film hydration method followed by extrusion through a
0.1 µm membrane. PAT was added in a 30:1 lipid:drug molar ratio. Diameter and size were
determined using dynamic light scattering. Following extrusion, liposomes were subjected to
size exclusion chromatography separate free PAT from encapsulated PAT.
Step

Diameter (nm)

Polydispersity index

Pre-extrusion

1921.3

0.265

0.1 µm membrane

131.8

0.096

Post-chromatography

131.1

0.104
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Table 4. Encapsulation efficiency of PAT loaded into Egg PC/Cholesterol (90:10) liposomes.
Liposomes were prepared using the thin film hydration method followed by extrusion through a
0.1 µm membrane. PAT was added in a 30:1 lipid:drug molar ratio. Size exclusion
chromatography was used to separate encapsulated PAT from free PAT. Liposomes were
disrupted and the percent of PAT loaded into liposomes was determined using HPLC. The
percent of PAT left in size exclusion column was also determined. Encapsulation efficiency was
calculated as follows: (Final PAT mass/Initial PAT mass) * 100%.

Encapsulation efficiency of PAT loaded
into Egg PC/cholesterol liposomes
Percent of PAT remaining on
chromatography column

57.7 %
8.4 %
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Table 5. DOPC/Cholesterol/Cardiolipin (95:5:5) liposomes loaded with PAT diameter and
polydispersity index after various stages of liposome preparation. PAT was added in a 30:1
lipid:drug ratio. Liposomes were prepared using the thin film hydration method followed by
extrusion through 0.8, 0.4, and 0.1 µm membranes. Liposome diameter and polydispersity index
was determined using dynamic light scattering.
Step

Diameter (nm)

Polydispersity index

Pre-extrusion

866.8

0.284

0.4 um membrane

272.9

0.160

0.1 um membrane

125.0

0.086

Post-chromatography

122.0

0.078
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Table 6. Encapsulation efficiency of PAT loaded into DOPC/Cholesterol/Cardiolipin (95:5:5)
liposomes. Liposomes were prepared using the thin film hydration method followed by extrusion
through a 0.1 µm membrane. PAT was added in a 30:1 lipid:drug molar ratio. Size exclusion
chromatography was used to separate encapsulated PAT from free PAT. Liposomes were
disrupted and the percent of PAT loaded into liposomes was determined using HPLC. The
percent of PAT left in size exclusion column was also determined. Encapsulation efficiency was
calculated as follows: (Final PAT mass/Initial PAT mass) * 100%.
Encapsulation efficiency of PAT loaded
into DOPC/Cholesterol/Cardiolipin
liposomes
Percent of PAT remaining on
chromatography column

68.4 %

5.9 %
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Table 7. Stability of DOPC/Cholesterol/Cardiolipin (95:5:5) liposomes loaded with PAT
extruded through a 0.4 µm or 0.1 µm. PAT was added in a 30:1 lipid:drug ratio. Prior to
extrusion through membranes, liposomes were prepared using the thin film hydration method.
Liposome diameter and polydispersity index was determined using dynamic light scattering.

Day

0.4 µm
membrane
diameter (nm)

0.1 µm
membrane
diameter (nm)

272.9

0.4 µm
membrane
polydispersity
index
0.160

125.0

0.1 µm
membrane
polydispersity
index
0.086

0
1

295.1

0.213

125.3

0.080

2

263.7

0.170

123.5

0.094

3

281.0

0.210

125.6

0.094

7

259.2

0.145

123.6

0.102

10

252.7

0.151

124.9

0.084

14

226.5

0.164

124.4

0.061
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Table 8. DOPC/Cholesterol/Cardiolipin/GM1 (89:5:5:1) liposomes loaded with PAT diameter
and polydispersity index after various stages of liposome preparation. PAT was added in a 30:1
lipid:drug ratio. Liposomes were prepared using the thin film hydration method followed by
extrusion through 0.2 and 0.1 µm membranes. Liposome diameter and polydispersity index was
determined using dynamic light scattering.

Step

Diameter (nm)

Polydispersity index

Pre-extrusion

1348.0

0.347

0.2 µm membrane

185.5

0.094

0.1 µm membrane

119.3

0.053

Post-chromatography

118.9

0.091
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Table 9. Comparison of diameter and polydispersity index between liposomes with different
compositions. DOPC and DOPC/GM1 (99.5:0.5) were prepared with and without loading PAT
(30:1 lipid:drug). DOPC/GM1 (98:2) and DOPC/GM1 (95:5) were loaded with PAT (30:1
lipid:drug). All liposomes were prepared using the thin film hydration method with extrusion
through a 0.1 µm membrane. Diameter and polydispersity index were assessed using dynamic
light scattering.

Mol percent GM1 in
DOPC Liposome
0
0.5
0
0.5
2
5

PAT Loaded into
Liposome
No
No
Yes
Yes
Yes
Yes

Diameter (nm)

Polydispersity Index

126.2
122.1
125.1
121.3
117.8
119.2

0.081
0.090
0.063
0.086
0.070
0.075
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A

Diameter of liposomes loaded with paclitaxel

Diameter (nm)

150
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120
110

100
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0
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Day

Polydispersity Index

B

DOPC

DOPC/GM1 (99.5:0.5)

DOPC/GM1 (98:2)

DOPC/GM1 (95:5)

Polydispersity Index of liposomes loaded with
paclitaxel
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Figure 7. Liposome stability of DOPC, DOPC/GM1 (99.5:0.5), DOPC/GM1 (98:2), and
DOPC/GM1 (95:5). A) Liposome diameter stability. B) Liposome polydispersity index stability.
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Percentage of Paclitaxel
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Encapsulation efficiency of paclitaxel loaded into
liposomes
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Figure 8. Encapsulation efficiency of PAT loaded into DOPC, DOPC/GM1 (99.5:0.5),
DOPC/GM1 (98:2), and DOPC/GM1 (95:5) liposomes. Liposomes were prepared by thin film
hydration with extrusion through a 0.1 µm membrane. PAT was added at a ratio of 30:1,
lipid:PAT. There is not a significant difference in encapsulation efficiency of PAT loaded into
the four different liposome formulations.
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Figure 9. Atomic force microscopy height trace (top) and 3D height map (bottom) of
DOPC/GM1 liposomes confirms a spherical morphology.
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Chapter 3: Assessment of GM1 to Improve Liposomal Transport of Paclitaxel Across an in
vitro Model of the Blood Brain Barrier
Abstract
Development of a novel drug delivery system that can bypass the blood brain barrier to treat
cerebral diseases such as intracranial atherosclerotic disease are needed. GM1 has previously
demonstrated the ability to cross the BBB. In this study, the liposomes containing varying
amounts of GM1 (0, 0.5, 2, and 5 mol %) were assessed for their ability to improve paclitaxel
(PAT) transport across the in vitro BBB. There was no difference in the amount of PAT
transported across hCMEC/d3 BBB endothelial cells between the DOPC/GM1 liposomes and the
control DOPC only liposomes. In the future, additional modifications to the liposomes are
needed to improve the transport of PAT loaded liposomes across the in vitro BBB.
1. Introduction
Drug coated balloons (DCBs) containing an excipient and antiproliferative drug are frequently
used to treat atherosclerotic diseases such as peripheral artery disease and help restore blood flow
while preventing restenosis or renarrowing of the artery. However, the use of DCBs to treat
intracranial atherosclerotic disease (ICAD) in the brain is limited12. One limitation of using
DCBs in the cranial arteries is the presence of the blood brain barrier (BBB). The most common
and effective antiproliferative drug used in DCBs is paclitaxel (PAT) 18-20; however, PAT has
poor BBB permeability23.Therefore, the presence of the BBB may prevent enough PAT from
crossing the BBB to be therapeutic and prevent the restenosis associated with balloon
angioplasty.
The monosialoganglioside GM1 has the potential to be used in a drug delivery system to
treat neurological disease to help overcome the BBB. In a study by Zou et al 2017, GM1
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micelles loaded with doxorubicin were able to cross the BBB in a zebrafish model. Moreover,
these GM1 micelles demonstrated high specificity for the brain in mice45. Importantly, PAT has
previously been loaded into GM1 micelles with high efficiency46. While utilizing GM1 as a drug
delivery vehicle for PAT in the form of a micelle system is promising, there are several
drawbacks. For example, isolating GM1 from mammalian sources is time consuming and results
in low yields. However, purchasing GM1 from a commercial source is often cost prohibitive.
To reduce the time and cost burden of utilizing GM1 micelles, GM1 may be incorporated
into a liposomal system which may help to reduce the amount of GM1 needed. Several studies
have previously incorporated GM1 into liposomes44,48-54. Moreover, a previous study
demonstrated the ability of GM1 liposomes to encapsulate drugs and target brain structures with
high specificity67.
The purpose of the current study is to assess the ability of GM1 liposomes to improve the
transport of PAT across an in vitro model of the BBB. GM1 will be incorporated into liposomes
made with 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), which is a lipid previously used
to synthesize liposomes incorporating GM148-50,52. An established Transwell model of the BBB
utilizing hCMEC/d3 cells68-70 will be used to determine if the presence of GM1 improves the
BBB permeability of PAT loaded liposomes in vitro.
2. Materials and Methods
2.1 Materials
Phosphate buffer saline (PBS), methanol, high performance liquid chromatography (HPLC)
grade water, acetonitrile, ethyl acetate, chloroform, collage type I rat tail, Dulbecco’s Phosphate
Buffer Saline (DPBS), hydrocortisone, hFGF-basic, L-Ascorbic acid, and hCMED/d3 cell line
were purchased from Milipore Sigma (St. Louis, MO). Ethanol (200 proof) was purchased from
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Fisher Scientific (Hanover Park, IL). DOPC and ganglioside GM1 (ovine brain) were purchased
from Avanti Polar Lipids (Alabaster, AL). EBM-2 Endothelial Cell Growth Basal Media was
purchased from Lonza (Walkersville, MD). Chemically Defined Lipid Concentrate, PenicillinStreptomycin (5000 U/mL), fetal bovine serum (FBS), and HEPES 1M were purchased from
Thermo Fisher Scientific (Waltham, MA). Paclitaxel (PAT) was purchased from ChemiTek
(Indianapolis, IN). Trypsin EDTA was purchased from ATCC (Manassas, VA).
2.2 Preparation of liposomes
DOPC and GM1 were dissolved in chloroform. PAT was dissolved in ethanol. Liposomes were
prepared using the thin film hydration method followed by extrusion55,61. DOPC, GM1, and PAT
in their respective organic solvent were added to a round bottom flask in the appropriate molar
ratios. The following molar ratios were used for the DOPC/GM1 liposomes: 100:0, 99.5:0.5,
98:2, 95:5 DOPC:GM1. PAT was added in a 30:1 lipid:drug molar ratio. Organic solvent was
evaporated using a rotary evaporator (Buchi) under vacuum. The round bottom flask rotated at
100 rpm in a 37°C water bath for 1 hour. The subsequent lipid thin film was placed under a high
vacuum (<1000 mTorr) overnight to remove residual solvent. The following day, PBS was added
to the lipid film, so the final concentration of lipid was 3 mM. The lipid film was then hydrated
on a rotary evaporator under atmospheric pressure at 200 rpm at 40°C for 1 hour. Next, the lipid
suspension underwent 5 freeze thaw cycles using a dry ice/ethanol bath and a 40°C water bath.
The lipid suspension was then extruded 19 times through a 0.1 µm polycarbonate membrane
(Avanti Polar Lipids). Liposome size and polydispersity index (PI) were determined using
dynamic light scattering (DLS) in a Beckman Delsa Nano C instrument. All liposomes used in
cell culture experiments were utilized within 3 days of initial preparation.
2.3 Cell culture
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The hCMEC/d3 cell was grown in EBM-2 media supplemented with the following: 5% FBS, 1%
penicillin/streptomycin, 10 mM HEPES, 1% lipid concentrate, 1.4 µM hydrocortisone, 5 µg/mL
ascorbic acid, and 1 ng/mL hFGF-basic. Prior to seeding, culture plates were coated with 6.7
µg/cm2 collagen type I (rat tail). Cells were incubated at 37°C in 5% CO2. Media was changed
every 2-3 days. At approximately 80% confluence, cells were subcultured.
2.4 Transwell model of the BBB
Prior to seeding cells, the Transwell insert was coated with 4 µg/cm2 collagen type I (rat tail).
The hCMEC/d3 cells were seeded onto the Transwell insert at a density of 50,000 cells/cm 2 in
the EBM-2 complete media described above. 400 µL of media was added to the apical side of
the Transwell and 1.2 mL was added to the basal side of the Transwell. A schematic of the
Transwell is described in Figure 10. Media was changed every 1-2 days. Beginning at day 3 or 4
post seeding, the transepithelial electrical resistance (TEER) was monitored using a EVOM2
Epithelial Voltohmmeter (World Precision Instruments). TEER was calculated as follows: (Rcells
– Rblank) X A (Ω cm2) where R is the measured electrical resistance and A is the area of the
Transwell insert. Cells were treated at day 10 when TEER was at least 30-50 Ω*cm2 in
accordance with the literature68,70-74.
2.5 Lucifer yellow assay
To assess the quality of the hCMEC/d3 tight junctions in the Transwell system, a lucifer yellow
assay was performed on day 10 post seeding. Briefly, cells in the Transwell were washed with
DPBS. 400 µL of 20 µM of lucifer yellow in DPBS was added to apical side of the Transwell
and 1.2 mL DPBS was added to basal side of the Transwell. Cells were treated in duplicate. At
0.5, 1, 1.5, and 2 hour timepoints, 200 µL was collected from the basal side of Transwell and
replaced with 200 µL fresh DBPS. In between timepoints, cells were incubated at 37°C in 5%
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CO2. The amount of lucifer yellow present was determined by reading the fluorescence at
excitation/emission wavelength 480/530 nm of the samples and calculating the concentration of
lucifer yellow using a standard curve. The apparent permeability coefficient (Papp) was calculated
as follows: [VB/(ACA0)] X (ΔCB/Δt) where VB is the volume in the basolateral compartment, A is
the surface area of the Transwell insert, CA0 is the initial concentration in the apical
compartment, and ΔCB/Δt is the change in concentration over time in the basal lateral
compartment.
2.6 Transport of liposomal PAT across the in vitro BBB
The Transwell model using hCMEC/d3 cells is described in section 2.4. On day 10, cells were
treated on the apical side of the Transwell with liposomes loaded with PAT. GM1 was present in
the DOPC liposomes in the following DOPC:GM1 molar ratios: 99.5:0.5, 98:2, or 95:5. DOPC
liposomes with no GM1 were used as a control. Cells were treated so the final concentration of
PAT in the apical side media was 10 µM, which is the equivalent to 3.4 µg PAT. Cells were
treated in triplicate and incubated at 37°C in 5% CO2. At the 0.5, 1, 1.5, and 2 hour timepoints,
0.2 mL of media was collected from the basal side of the Transwell and replaced with 0.2 mL of
fresh complete EBM-2 media. At 2 hours, 0.2 mL of media was also collected from apical side
of the Transwell to determine the amount of PAT that did not cross the hCMEC/d3 cells. Ethyl
acetate (2 mL) was added to the collected aliquots to disrupt the liposomes and release the PAT
into the organic solution. The solution was centrifuged to separate the organic and aqueous
phases. The organic phase was then collected and evaporated at room temperature in a fume
hood. Once the ethyl acetate was evaporated, the PAT was resuspended in ethanol. The amount
of PAT present was quantified using high performance liquid chromatography (HPLC),
described in section 2.8.
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2.7 Intracellular uptake of liposomal PAT by hCMEC/d3 cells
The Transwell model using hCMEC/d3 cells is described in section 2.4. Following 2 hours of
treatment with PAT containing liposomes described in section 2.6, hCMEC/d3 cells were
washed 3 times with DPBS. Trypsin was then added to dissociate the cells from Transwell insert.
Ethyl acetate was then added to lyse the cells. The solution was centrifuged to separate the
organic and aqueous phases. The organic phase was then collected and evaporated at room
temperature. Once evaporation was complete, ethanol was added and the amount of PAT present
was quantified using HPLC, described in section 2.8.
2.8 Drug quantification
Samples containing PAT in ethanol were quantified using a previously developed method using
HPLC25. HPLC analyses was performed on a Waters e2695 system equipped with a Waters
2489 UV/Vis detector (Waters Corporation, Milford, MA) and a Nova-Pak column (3.9 mm x
150 mm, particle size: 4 μm). A 45:55 water:acetonitrile mobile phase was used. The column
temperature was set to 35°C, the flow rate was set to 1 mL/min, and 10 µL of sample was
injected for analysis. The UV detector wavelength was set to 227 nm. Prior to sample analysis, a
PAT calibration was prepared to calculate the concentration of PAT present in the sample.
Concentration was determined by measuring the area under the curve for each sample.
3. Results
3.1 Transport of PAT across an in vitro BBB using DOPC/GM1 (99.5:0.5) liposomes
The Transwell model of the BBB using hCMEC/d3 cells was used to assess the ability of GM1
to improve the transport of PAT loaded liposomes across an in vitro BBB. On day 10 post
seeding, the hCMEC/d3 cells had an average TEER of 49.0 ± 5.2 Ω•cm2, indicating the presence
of tight junctions. The Papp for the lucifer yellow assay was calculated to be 2.69 x 10-4 cm/min,
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which is smaller than the accepted lucifer yellow Papp for the hCMEC/d3 cell line (1.33 x 10-3

cm/min), indicating acceptable rejection of lucifer yellow by the cells75. Together, the TEER and
lucifer yellow Papp indicated the presence of tight junctions. Therefore, cells were treated on day
10 with PAT loaded DOPC/GM1 (99.5:0.5) or PAT loaded DOPC liposomes (n=3). Prior to
treatment, the diameter and PI of the liposomes were assessed. The DOPC liposomes had a
diameter of 125.1 nm and PI of 0.063 while the DOPC/GM1 (99.5:0.5) liposomes had a diameter
of 121.9 nm and PI of 0.084 (Table 10). The ability of a low mol % of GM1 to improve transport
of PAT loaded liposomes across the in vitro BBB was assessed by measuring the amount of PAT
present in the basal Transwell compartment at 0.5, 1, 1.5, and 2 hour timepoints using HPLC.
The percentage of initial PAT added to the apical compartment that ended up in the basal
compartment was calculated and compared between the two treatment groups (Figure 10). There
was no difference in the percentage of PAT that crossed the in vitro BBB between the two
treatment groups at any timepoint. This indicates that a low mol % of GM1 in a liposome does
not improve the transport across the in vitro BBB. The amount PAT remaining in the apical
compartment was also assessed for each treatment group. Around 1-1.2 µg of PAT remained in
the apical compartment (Figure 11). Because only around 10 % or 0.34 µg of PAT (Figure 10)
was able to cross the hCMEC/d3 cells, a significant portion of PAT is unaccounted for and may
have been taken up by the hCMEC/d3 cells.
3.2 Transport of PAT across an in vitro BBB using DOPC/GM1 (98:2) and DOPC/GM1
(95:5) liposomes
Because GM1 in a 99.5:0.5 DOPC to GM1 mol ratio did not improve the transport of liposomal
PAT across the in vitro BBB, DOPC/GM1 (98:2) and DOPC/GM1 (95:5) liposomes were
assessed to see if the higher amount of GM1 would improve transport. The Transwell model of
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the BBB using hCMEC/d3 cells was used and cells were treated with PAT loaded DOPC,
DOPC/GM1 (98:2), or DOPC/GM1 (95:5) liposomes (n=3) on day 10 post seeding. At day 10,
the average TEER for the hCMEC/d3 was 51.7 ± 6.9 Ω cm2, indicating the presence of tight
junctions. The Papp for the lucifer yellow assay was calculated to be 2.7675 x 10-4 cm/min, which
is acceptable for the hCMEC/d3 cell line and indicates the quality of the tight junctions. Prior to
treatment, the DOPC liposomes were determined to have a diameter of 130.4 nm and a PI of
0.066. DOPC/GM1 (98:2) liposomes had a diameter of 117.8 and PI of 0.070 and the
DOPC/GM1 (95:5) had a diameter of 199.2 and PI of 0.075 (Table 11). Following addition of
the PAT loaded liposomes to the apical side of the Transwell, samples were collected at 0.5, 1,
1.5, and 2 hour timepoints from the basal side of the Transwell. The percentage of initial PAT
added to the apical compartment that ended up in the basal compartment was calculated and
compared between the three treatment groups (Figure 12). There was no difference in the
percentage of PAT that crossed the in vitro BBB between the three treatment groups at any
timepoint. This indicates that GM1 does improve the transport of liposomal PAT when present in
98:2 or 98:5 DOPC to GM1 mol ratios.
3.3 Cellular uptake of liposomes loaded with PAT
In section 3.1, it was observed that a significant amount of PAT (~1.86-2.06 µg) was
unaccounted for in the Transwell after the 2 hour treatment with PAT loaded liposomes and
calculating the amount of PAT present in the basal and apical compartments. Therefore, it was
hypothesized that some PAT may have ended up in the hCMEC/d3 cells. To assess cellular
uptake of PAT loaded DOPC, DOPC/GM1 (98:2), and DOPC/GM1 (95:5) liposomes, the
hCMEC/d3 cells in section 3.2 were lysed following the 2 hour incubation with the liposomes to
release the cellular contents. HPLC was then performed to determine the amount of PAT present
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in the cells. The cellular uptake by hCMEC/d3 cells treated with DOPC, DOPC/GM1 (98:2), or
DOPC/GM1 (95:5) liposomes was calculated to be around 150 ng for all three treatment groups
(Figure 13A). The amount of PAT present in the apical Transwell compartment after 2 hours of
treatment was determined to be around 2.5 µg for all three treatment groups and after 2 hours of
treatment (Figure 13B), roughly 10% of the initial PAT in the apical compartment (or .34 µg)
crossed over the hCMEC/d3 cells into the basal compartment (Figure 12). Therefore, in total,
around 3 µg of the initial 3.4 µg of PAT was recovered.
4. Discussion
The development of a drug delivery system to bypass the BBB while maintain BBB integrity
continues to be an obstacle for the treatment of a variety of neurological diseases including
ICAD. While DCBs for the treatment ICAD have shown some promise, the PAT used in a DCB
has poor BBB permeability23. Here, we sought to address this issue by incorporating GM1 into
DOPC liposomes to load PAT and improve the transport of PAT across an in vitro BBB model.
Liposomes with a low mol % of GM1 (DOPC/GM1 99.5:0.5) did not improve the
transport of PAT across the in vitro BBB. Because 0.5 mol % GM1 is low, we hypothesized that
there was not enough GM1 present in the liposome to affect BBB permeability. Therefore, we
assessed liposomes with a higher mol % of GM1 and their ability to improve PAT transport
across the in vitro BBB. However, DOPC/GM1 (98:2) and DOPC/GM1 (95:5) liposomes did
improve the transport of PAT across the in vitro BBB.
It is possible that there was not enough GM1 present in any of the liposome formulations
to affect the in vitro BBB permeability. However, increasing the mol % of GM1 in the liposomes
may not be option because GM1 can significantly affect the structure and integrity of a liposome.
The affect GM1 has on liposomal structure and integrity also increases with increasing mol % of
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GM149. The only way to increase the amount of GM1 to improve PAT transport across the BBB
may be to use pure GM1 in the form of micelles. GM1 in the form of micelles was used as drug
delivery system in Zou et al to deliver doxorubicin across the BBB45. However, this option is not
economically sustainable for many academic intuitions due to the costly nature of GM1.
The model used in study may have also affected the ability of GM1 to bypass the BBB.
While in vitro models of the BBB such as the Transwell model with hCMEC/d3 cells are
important for initial evaluation of BBB permeability, in vitro models including hCMEC/d3 cells
have significant limitations. For example, monocultures of cerebral endothelial cells lack the
presence of other components of the neurovascular unit, resulting in paracellular barrier
properties that do not recapitulate the in vivo BBB. One way to improve a monoculture of
hCMEC/d3 cells may be to use a coculture model where the endothelial cells are cultured with
other cerebral cells such as pericytes and astrocytes76. It is also possible GM1 utilizes a
transporter not present in the hCMEC/d3 cell line. In the study by Zou et al, the authors studied
GM1 BBB permeability in a Zebrafish model45; therefore, the Zebrafish BBB may have a
transporter for GM1 not present in hCMEC/d3 cells.
Another possibility is that the BBB permeability of GM1 is not as robust as reported in
Zou et. al. Because of its neuroprotective properties, GM1 has been studied as a therapeutic for a
variety of neurodegenerative diseases including Parkinson’s disease. Several of these studies
report poor BBB permeability or unclear BBB permeability of GM177-80. However, it is
important to note that in these studies, GM1 itself is the therapeutic agent and not used in a
micelle or liposomal system as a drug delivery vehicle. This may account for the discrepancy in
the BBB permeability of GM1.
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Lastly, it is possible that a longer treatment time is needed to see an effect of GM1 on
liposomal PAT in vitro BBB permeability. In the current study, hCMEC/d3 cells were only
treated with PAT loaded liposomes for 2 hours. However, a longer treatment times in vitro may
not be therapeutically relevant has a DCB is only in contact with an arterial wall for a few
minutes. Moreover, we demonstrated the uptake of PAT by hCMEC/d3 cells. Because PAT is
cytotoxic, a longer treatment time with PAT may comprise the integrity of the tight junctions.
5. Conclusion
GM1 did not improve the transport of PAT loaded liposomes across the in vitro BBB in any of
the liposomal formulations tested. This may have been the result of several factors including the
low mol % of GM1 used, the short treatment time, the model utilized, and/or the nature of GM1.
In the future, we may need to use an alternative modification to improve the transport of
liposomal PAT across the in vitro BBB.
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Table 10. Diameter and polydispersity index of control and 0.5% GM1 liposomes prior to
treating hCMEC/d3 cells. Liposomes were loaded with PAT (1:30 PAT:Lipid) and extruded
through a 0.1 µm membrane. Diameter and polydispersity index were assessed using dynamic
light scattering.

Composition
DOPC/PAT
DOPC/GM1/PAT (99.5:0.5)

Diameter (nm)
125.1
121.9
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Polydispersity Index
0.063
0.084

A

Transwell Insert

Apical Side
hCMEC/d3 Cells
Basal Side

Tissue Culture Well
B

Percentage of PAT (%)

Percentage of PAT Transported accross hCMEC/d3
Cells
100
90
80
70
60
50
40
30
20
10
0
0.5

1

1.5

2

Time (h)
DOPC

DOPC/GM1 (99.5:0.5)

Figure 10. Transport of PAT across an in vitro model of the BBB using liposomes with 0.5 mol
% GM1. The hCMEC/d3 cell line was grown on Transwell inserts for 10 days while monitoring
the Transendothelial electrical resistance (TEER), which is an indicator for the formation of tight
junctions characteristic of the BBB. On day 10 when TEER was at least 30-50 Ω*cm2, cells were
treated with DOPC/PAT or DOPC/GM1/PAT liposomes on the apical side of Transwell insert.
Samples were obtained from the basal side of Transwell insert at various timepoints. The amount
of PAT present on the basal side of the Transwell insert was determined using HPLC. A)
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Schematic of the Transwell hCMEC/d3 in vitro BBB. B) Ratio of PAT that was transported
across the in vitro BBB. There was not significant difference in the ratio of PAT transported
between the two treatment groups. Error bars represent mean ± standard deviation.
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Amount of PAT Remaining in Apical Compartement
after 2 hours
1.6

Paclitaxel Amount (µg)

1.4
1.2
1
0.8
0.6
0.4
0.2
0
DOPC

DOPC/GM1 (99.5:0.5)

Figure 11. Amount of PAT not transported across hCMECd/3 cells after 2 hours. The
hCMEC/d3 cell line was grown on Transwell inserts for 10 days while monitoring the
Transendothelial electrical resistance (TEER), which is an indicator for the formation of tight
junctions characteristic of the BBB. On day 10 when TEER was at least 30-50 Ω*cm2, cells were
treated with DOPC or DOPC/GM1 (99.5:0.5) liposomes loaded with PAT on the apical side of
Transwell insert. Each well was treated with a total of 3.4 µg of PAT. Following two hours
treatment, the amount of PAT remaining on the apical side of the Transwell was determined
using HPLC. Error bars represent mean ± standard deviation.
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Table 11. Diameter and polydispersity index of control, 2 mol % GM1, and 5 mol % GM1
liposomes prior to treating hCMEC/d3 cells. Liposomes were loaded with PAT (1:30 PAT:Lipid)
and extruded through a 0.1 µm membrane. Diameter and polydispersity index were assessed
using dynamic light scattering.

Composition
DOPC
DOPC/GM1 (98:2)
DOPC/GM1 (95:5)

Diameter (nm)
130.4
117.8
119.2
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Polydispersity Index
0.066
0.070
0.075

Percentage of Paclitaxel Transported
(%)

Percentage of Paclitaxel Transported across hCMEC/d3 cells
20

15
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5
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0.5
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DOPC/GM1 (98:2)

DOPC/GM1 (95:5)

Figure 12. Transport of PAT across an in vitro model of the BBB using liposomes with 2 mol %
and 5 mol % GM1. The hCMEC/d3 cell line was grown on Transwell inserts for 10 days while
monitoring the Transendothelial electrical resistance (TEER), which is an indicator for the
formation of tight junctions characteristic of the BBB. On day 10 when TEER was at least 30-50
Ω*cm2, cells were treated with DOPC, DOPC/GM1 (98:2), or DOPC/GM1 (95:5) liposomes
loaded with PAT on the apical side of Transwell insert. Samples were obtained from the basal
side of Transwell insert at various timepoints. The amount of PAT present on the basal side of
the Transwell insert was determined using HPLC. The ratio of PAT that was transported across
the in vitro BBB is shown. There was not significant difference in the ratio of PAT transported
between the three treatment groups. Error bars represent mean ± standard deviation.
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Amount of Paclitaxel in hCMEC/d3 Cells after 2 hours
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Figure 13. Cellular uptake of PAT by hCMEC/d3 cells. The hCMEC/d3 cell line was grown on
Transwell3 inserts for 10 days while monitoring the Transendothelial electrical resistance
(TEER), which is an indicator for the formation of tight junctions characteristic of the BBB. On
day 10 when TEER was at least 30-50 Ω*cm2, cells were treated with DOPC, DOPC/GM1
(98:2), or DOPC/GM1 (95:5) liposomes loaded with PAT on the apical side of Transwell insert.
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Each well was treated with a total of 3.4 µg of PAT. A) Following two hours treatment, the
amount of PAT remaining on the apical side of the Transwell was determined using HPLC. B)
Following 2 hours of treatment, hCMEC/d3 cells were lysed and the amount of PAT present was
determined using HPLC. Error bars represent mean ± standard deviation.
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Chapter 4: Preparation of Thin Films Containing Liposomes and Polyethylene Oxide
Abstract
Drug coated balloons (DCBs) have several characteristics that make them appealing for the
treatment of intracranial atherosclerotic disease. However, the blood brain barrier (BBB) may
prevent enough drug from being delivered to the arterial wall to be therapeutic. One way to
overcome the BBB may be to use liposomes. These liposomes may then be incorporated with a
polymer excipient such as polyethylene oxide (PEO) for future use as a balloon coating. In this
study, thin films containing PEO only, PEO with DOPC liposomes, and PEO with DOPC/GM1
liposomes. The ability of liposomes to maintain their structure was assessed using scanning
electron microscopy (SEM). SEM provide evidence that liposomes maintain their structure when
added to the PEO films. The ability of liposomes to crosslink with PEO for controlled release
from the in films was also assessed by determining the time for each film to dissolve in an
aqueous environment. There was no difference in the time to dissolve between the PEO +
liposome thin films and PEO only controls, suggesting that additional liposomal functional
groups are needed to facilitate the interaction between liposomes and PEO.
1. Introduction
Drug coated balloons (DCBs) are a technology used to treat a variety of atherosclerotic diseases
and generally consist of an antiproliferative drug such as paclitaxel (PAT) and a polymer
excipient. However, up to 80% of the drug may be lost in transit to the treatment site, resulting in
a subtherapeutic amount of drug delivered to the lesion24. This is especially concerning for the
treatment of intracranial atherosclerotic disease (ICAD), as PAT is cytotoxic and may have
adverse effects in the brain.
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A study by Anderson et al developed thin films consisting of the polymer polyethene
oxide (PEO) and PAT. By adjusting the wt/v % of PEO in the films, the authors were able to
control release of PAT at specific timepoints to help reduce the amount of PAT loss in transit to
the treatment site and maximize drug delivery to the lesion24. Eventually, these thin films were
used as a coating for both a single-release and a multiple-release DCB for the treatment of
peripheral artery disease. An additional advantage of theses PEO and PAT DCBs is their low
particulate shed, which helps to reduce the risk of embolism following treatment 25,26. This is
important in the brain, where particulate causing embolisms can be especially deadly 12.
Along with the concerns of PAT cytotoxicity and particulate shed, another limitation of
using DCBs to treat ICAD is the BBB, as PAT has poor BBB permeability23. One way to address
this issue may be to use the ganglioside GM1 as a drug delivery vehicle for the transport of PAT
across the BBB. A previous study utilized GM1 in the form of micelles to load doxorubicin
(DOX) and transport the DOX across the in vivo BBB in zebrafish45. However, the use of GM1
is often cost prohibitive; therefore, it may be useful to incorporate GM1 into a liposome to
reduce the amount of GM1 needed. These GM1 liposomes may then be used to transport PAT
across the BBB.
In the current study, we propose to incorporate DOPC and DOPC/GM1 liposomes into
PEO thin films. Scanning electron microscopy (SEM) will be used to assess incorporation of the
liposomes into films and integrity of the liposomes when added to PEO. The ability of liposomes
to crosslink with PEO and be released at specific intervals from the films will also be assessed.
2. Methods
2.1 Materials
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Phosphate buffer saline (PBS), chloroform, and polyethylene oxide (PEO; average Mv 100,000)
were purchased from Millipore Sigma (St. Louis, MO). DOPC and ganglioside GM1 (ovine
brain) were purchased from Avanti Polar Lipids (Alabaster, AL).
2.2 Preparation of liposomes
DOPC and GM1 were dissolved in chloroform. Liposomes were prepared using the thin film
hydration method followed by extrusion55,61. DOPC and GM1 were added to a round bottom
flask in the following DOPC/GM1 molar ratios: 100:0 and 99.5:0.5. Organic solvent was
evaporated using a rotary evaporator (Buchi) under vacuum. The round bottom flask rotated at
100 rpm in a 37°C water bath for 1 hour. The subsequent lipid thin film was placed under a high
vacuum (<1000 mTorr) overnight to remove residual solvent. The following day, deionized
water (for SEM) or PBS (for film dissolution) was added to the lipid film, so the final
concentration of lipid was 3 mM. The lipid film was then hydrated on a rotary evaporator under
atmospheric pressure at 200 rpm in a 40°C water bath for 1 hour. Next, the lipid suspension
underwent 5 freeze thaw cycles using a dry ice/ethanol bath and a 40°C water bath. The lipid
suspension was then extruded 19 times through a 0.1 µm polycarbonate membrane (Avanti Polar
Lipids). Liposome size and polydispersity index (PI) were determined using dynamic light
scattering (DLS) in a Beckman Delsa Nano C instrument. All liposomes were incorporated into
PEO thin films within 3 days of initial preparation.
2.3 Preparation of PEO thin films
A PEO solution was prepared by adding 0.9 g PEO to 8 mL deionized water. PEO was allowed
to dissolve overnight with stirring. The following day, 1 mL of 3 mM DOPC or DOPC/GM1
liposomes was added to the PEO and allowed to stir for 1 hour. As a control, 1 mL of deionized
water with no liposomes was also added to a PEO solution and allowed to stir for 1 hour. The
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final concentration of PEO in the liposome solution was 10% w/v. The PEO/DOPC,
PEO/DOPC/GM1, and PEO solutions were transferred to 6 cm diameter glass petri dishes and
placed in a 50°C oven under vacuum. The water was allowed to evaporate from the films for 72
hours. After 72 hours, the films were allowed to cool for 30 min prior to use.
2.4 Scanning electron microscopy of PEO and liposome thin films
The following thin films were prepared in section 2.3: PEO, PEO + DOPC liposomes, and PEO
+ DOPC/GM1 liposomes. Films were cut and gold coated prior to imaging. Films were imaged
with a Quanta 450 SEM (FEI, Hillsboro, OR).
2.5 Dissolving PEO and liposome thin films
The ability of liposomes to crosslink with PEO within a thin film was assessed using a method
modified from Anderson et al 201624. Briefly, 2 cm x 2 cm sections were cut from the thin films
prepared in section 2.3. Next, each film was placed in 25 mL of PBS in a 37°C water bath with
circulation. 0.05% Tween-20 was added to the PBS to maintain sink conditions. At 0.5, 1, 2, 3, 5,
and 7 minutes, the film was picked up out of the PBS with a forceps. The timepoint at which the
film was not intact and could no longer be picked up with a forceps was marked as the time it
took for the film to dissolve. A longer dissolve time compared to the PEO only control would
indicate increased interactions between the PEO and liposomes.
3. Results
3.1 Morphology of PEO and liposome thin films
Prior to incorporating into thin films, the diameter and PI of liposomes was assessed. DOPC
liposomes had a diameter of 114.9 nm and a PI of 0.134. DOPC/GM1 liposomes had a diameter
of 122.9 nm and a PI of 0.103 (Table 12). Diameters for both liposome formulations are
consistent with extrusion through a 0.1 µm membrane and PIs indicate acceptable uniformity of
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liposomes. SEM of the PEO only films revealed relatively smooth, flat films as expected because
no liposomes were added. In contrast, PEO + DOPC liposome films had distinct, spherical
protrusions in the film, indicated by the red arrows in Figure 14. It is possible these protrusions
are the DOPC liposomes. When measured on SEM, these protrusions ranged in size from ~130160 nm in diameter, which is slightly larger than the 114.9 nm diameter measured with DLS.
This larger diameter may be the result of the gold coating added to the film prior to the SEM.
Interestingly, PEO + DOPC/GM1 liposome films did not have as pronounced protrusions as the
PEO + DOPC liposome films but still more pronounced than the PEO only control (Figure 14).
3.2 Assessing the interaction between PEO and liposomes within thin films
Prior to incorporating into thin films, the diameter and PI of liposomes was assessed. DOPC
liposomes had a diameter of 126.2 nm and a PI of 0.081. DOPC/GM1 liposomes had a diameter
of 122.1 nm and a PI of 0.090 (Table 13). Diameters for both liposome formulations are
consistent with extrusion through a 0.1 µm membrane and PIs indicate acceptable uniformity of
liposomes. When added to PBS, PEO films were dissolved by 1 minute, PEO + DOPC liposome
films were dissolved by 2 minutes, and PEO + DOPC/GM1 liposomes were dissolved by 30
seconds. Because the dissolve times of the films containing liposomes were not significantly
longer than the PEO only film, there is likely not sufficient interactions between the liposomes
and PEO for crosslinking and subsequent controlled release of liposomes from the films. In fact,
the PEO + DOPC/GM1 liposome films took less time to dissolve than the PEO only film control
(Figure 15).
4. Discussion
Controlled release of PAT from a DCB is important because it reduces drug loss to the blood
stream and maximizes the amount of drug delivered to the atherosclerotic lesion 24. This is
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especially important in the brain as PAT is cytotoxic and may result in adverse effects.
Moreover, the presence of the BBB may prevent enough PAT from entering the arterial wall to
be therapeutic23. As a result, a patient may have to undergo additional treatments, put the patient
at increased risk of complications. One way to improve the transport of PAT across the BBB is
to use liposomes as a drug delivery vehicle. In addition, these liposomes can be modified with
molecules such as GM1 to improve BBB permeability45. In this study, we assessed the ability of
liposomes to interact with PEO for controlled release from a thin film.
SEM of the PEO thin films revealed the presence of protrusions in the PEO + DOPC
films that are consistent with size and morphology of liposomes. This may indicate that when
added to the PEO, liposomes maintain their morphology and integrity. It is important liposomes
maintain their morphology and integrity in the films because they are required to transport the
PAT across the BBB. Interestingly, the PEO + DOPC/GM1 liposome thin films did not have
protrusions as pronounced as the PEO + DOPC liposome thin films. This may indicate that the
presence of GM1 may affect the morphology and integrity of the liposomes when added to PEO.
The dissolve times for the PEO, PEO + DOPC, and PEO + DOPC/GM1 thin films were
not considerably different. This indicates that there is likely not a sufficient interaction between
the PEO and liposomes for controlled release of the liposomes from the film. In the case of PAT,
there are several -OH groups available that may help to facilitate the crosslinking between PAT
and PEO. This may be the reason the release of PAT from PEO films could be controlled in the
study by Anderson et al 201624. The DOPC lipid lacks such functional groups for sufficient
crosslinking with PAT. In contrast, the GM1 ganglioside does have some -OH functional groups
that could potentially be used for crosslinking with PAT. However, only 0.5 mol % of GM1 was
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present in the DOPC liposomes. Therefore, it is possible there was not enough GM1 present for
crosslinking with PEO.
In the future, functionalized lipids may be added to the liposomes to help facilitate
sufficient interactions between PEO and the liposomes for crosslinking and controlled release.
Likely candidates are functionalized lipids with -OH and carboxyl groups for interaction with
PEO.
5. Conclusion
The DOPC and DOPC/GM1 liposome formulations used in the present study do not have
sufficient functional groups for interaction with PEO for controlled release. However, there is
evidence that liposomes maintain their morphology and integrity when added to the PEO film. In
the future, functionalized lipids will need to be added to the DOPC liposomes to improve
interaction with PEO.
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Table 12. Diameter and polydispersity index of DOPC and DOPC/GM1 (99.5:0.5) liposomes for
SEM of thin films. Liposomes were prepared via thin film hydration followed by extrusion
through a 0.1 µm membrane. Diameter and polydispersity index were assessed using dynamic
light scattering.

Composition
DOPC
DOPC/GM1 (99.5:0.5)

Diameter (nm)
114.9
122.9
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Polydispersity Index
0.134
0.103

PEO

PEO+DOPC

PEO+DOPC/GM1

Figure 14. Scanning electron microscopy of thin films containing PEO, PEO with DOPC
liposomes, or PEO with DOPC/GM1 liposomes.
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Table 13. Diameter and polydispersity index of DOPC and DOPC/GM1 (99.5:0.5) liposomes for
thin film dissolution. Liposomes were prepared via thin film hydration followed by extrusion
through a 0.1 µm membrane. Diameter and polydispersity index were assessed using dynamic
light scattering.

Composition
DOPC
DOPC/GM1 (99.5:0.5)

Diameter (nm)
126.2
122.1
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Polydispersity Index
0.081
0.090

Time for Thin Films to Dissolve
7

Time (min)

6
5
4
3
2
1
0

PEO

PEO + DOPC Liposomes

PEO + DOPC/GM1
Liposomes

Figure 15. Time for PEO thin films containing liposomes to dissolve. Thin films containing
PEO, PEO with DOPC liposomes, or PEO with DOPC/GM1 liposomes were dissolved in 37°C
PBS and the time it took for films to dissolve was recorded. There was not a significant
difference in the time to dissolve between the PEO only films and liposome containing films,
indicating a lack of interaction between the liposomes and PEO.
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Chapter 5: Overall Conclusions and Future Directions
1. Conclusions
Intracranial atherosclerotic disease (ICAD) is the build-up of plaque within the cerebral arteries.
If left untreated, the plaque may block proper blood flow or rupture, resulting in a stroke. While
drug coated balloons (DCBs) are widely used to treat other atherosclerotic diseases such as
peripheral artery disease, their use in the brain remains limited. One such limitation is the poor
blood brain barrier (BBB) permeability of PAT and its cytotoxicity, which can cause adverse
effects in the brain. Therefore, a targeted drug delivery system is need for PAT to improve its
BBB permeability and specificity to improve treatment outcomes for patients suffering from
ICAD. This dissertation focused on preparing a liposome drug delivery vehicle for PAT that
incorporates the molecule GM1. First, GM1 was incorporated in liposomes loaded with PAT.
Next, these GM1 liposomes loaded with PAT were assessed in an in vitro model of the BBB to
determine if the presence of GM1 improves the transport of PAT across the in vitro BBB. Lastly,
these GM1 liposomes were combined into the PEO thin film technology used by the Tailored
Medical Devices (TMD) DCBs for controlled release.
The first aim of this dissertation was to prepare liposomes incorporating GM1 and to load
PAT into these liposomes. After troubleshooting and modifying several aspects of liposome
preparation, DOPC, DOPC/GM1 (99.5:0.5 mol ratio), DOPC/GM1 (98:2 mol ratio), and
DOPC/GM1 (95:5 mol ratio) liposomes loaded with PAT were successfully prepared. These
formulations resulted in liposomes around 120 nm in diameter with a high degree of uniformity.
In terms of diameter and polydispersity index, these liposomes were stable for at least 7 days,
with some formulations stable up to 56 days. Moreover, there was a high encapsulation
efficiency of PAT of 60-70 %, depending on the formulation. Atomic force microscopy also
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revealed a spherical morphology indicative of liposomes. Taken together, these results indicated
the successful preparation of DOPC/GM1 liposomes loaded with PAT.
Because PAT has poor BBB permeability, it is important for the drug delivery vehicle
carry PAT to be able to cross the BBB so enough drug can be delivered to the treatment site.
Therefore, the second aim of this dissertation was to assess the ability of PAT loaded GM1
liposomes to cross an in vitro model of the BBB. When present at 0.5 mol % in DOPC
liposomes, GM1 did not improve the transport of PAT across the in vitro BBB compared to
DOPC liposomes without PAT. Therefore, the amount of GM1 was increased in the DOPC
liposomes and tested in the in vitro model. When present at 2 and 5 mol % in DOPC liposomes,
GM1 did not improve the transport of PAT across the in vitro BBB. Therefore, it was included
that GM1 does not improve the transport of PAT loaded liposomes across the in vitro BBB.
The DCB technology developed by TMD has several advantages over other DCBs
currently available in the market. Once advantage is the ability to control the release of PAT
from the balloon coating so PAT is released at specific timepoints corresponding to key events
during an angioplasty treatment. Moreover, the PEO/PAT coating has low particulate shed
compared to other commercially DCBs. Because particulate shed is associated with an increased
risk of embolism formation, this feature of the TMD DCBs is especially appealing for potential
use in the cerebral vasculature. Therefore, the third aim of this dissertation was to assess the
ability of GM1 liposomes to crosslink with PEO for controlled release. DOPC and DOPC/GM1
(99.5:0.5 mol ratio) were added to PEO to prepare thin films. Scanning electron microscopy
revealed the presence protrusions consistent with liposomes dispersed throughout the
PEO+DOPC liposome thin film. This provided evidence that liposomes remain intact when
added to PEO. While the protrusions were not as pronounced in the PEO+DOPC/GM1 liposome
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thin films, they were still more pronounced than what was observed in the flat, PEO only thin
film control. When dissolved in 37 ºC PBS, all three thin film formulations had a similar dissolve
time. This indicates there is likely not a sufficient interaction between PEO and the DOPC or
DOPC/GM1 liposomes to facilitate crosslinking and controlled release from the films.
Thus, this dissertation studied the feasibility of incorporating GM1 into PAT loaded
liposomes and the ability of DOPC/GM1 liposomes to cross the in vitro BBB and to interact with
PEO for controlled release from PEO films.
2. Future Directions
Modifications may be added to the liposomes to improve stability, BBB permeability,
and interactions with PEO. Cholesterol may be added to improve stability. PEGylation of the
liposomes may also be beneficial to further improve both stability and BBB permeability 36,42.
The addition of ligands known to interact with receptors on the endothelial cells comprising the
BBB may also be added to improve transport across the BBB42. For example, transferrin may be
added as this is a known ligand for receptors on the BBB73. The addition of sugar groups or other
functionalized lipids containing hydroxides or amino groups may also be added to facilitate
crosslinking with PAT for controlled release from thin films.
Different lipids or combination of lipids may be used to prepare the liposomes as
different lipids may interact with the cell membrane of endothelial cells of the BBB differently,
affecting transport the transport of liposomes across the cells. For example, cationic lipids may
help improve transport by interacting with anionic components in the cell membrane, thus
facilitating adsorptive-mediated endocytosis42,81.
The hCMEC/d3 Transwell model utilized to access BBB permeability of liposomes has
several limitations68. It may be beneficial to utilize a more robust model of the BBB such as a co75

culture with astrocytes and pericytes that better recapitulates the in vivo BBB environment 68,82,83.
In addition, the use of a positive control that is known to cross the in vitro BBB may be used to
confirm the efficacy of the model.
The current study assessed the presence of PAT in the basal side of the Transwell system
and within endothelial cells. Confirming the presence of liposomes in addition to PAT may also
be beneficial as it is not clear the source of the PAT. It is possible the PAT present in the basal
side of the Transwell is free PAT that crossed the hCMEC/d3 down its concentration gradient. In
addition, due the highly lipophilic nature of PAT, it is possible the PAT present with the
hCMEC/d3 cells came from free PAT and not PAT encapsulated within liposomes. In addition, it
is possible that once the liposomes encounter the cell membrane of hCMEC/d3 cells, the
liposomes merge with the cell membrane and do not remain liposomes. The use of radiolabeled
liposomes may help to confirm the actual uptake and crossing of liposomes and not just PAT 84,85.
Once a liposome formulation that can cross the in vitro BBB and crosslink with PEO for
controlled release is identified, further characterizations will be needed. This will include the
drug release profile for PAT from the liposomes36. The stability of the liposomes will also need
to be examined. This may be achieved by monitoring diameter and polydispersity index using
DLS along with microscopy techniques such as AFM to confirm the stability of the liposome
structure36,64. Stability studies will need to be performed at different temperatures as well to
correspond with storage conditions and performance within the body. In addition to DLS and
microscopy techniques, the zeta potential will also provide insight into stability as this will
provide insight into whether the liposomes will aggregate together or remain dispersed36,43.
Fourier-Transform infrared spectroscopy may also be performed to confirm the composition of
the liposomes36. Because the crystallinity of PAT has important implications for tissue retention
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time, tissue solubility, and particulate shed, differential scanning calorimetry may also be
performed to determine the crystalline state within the liposomes21,27.
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